119th Congress · introduced in the House · Jan 16, 2026
ACE Agriculture Act
Official title from Congress.gov
Latest action (Mar 20, 2026): Referred to the Subcommittee on Conservation, Research, and Biotechnology.
View on Congress.govPolicy area: Agriculture and Food
Congressional Research Service summary, version: Introduced in House (Jan 16, 2026)
Advancing Cutting Edge Agriculture Act or the ACE Agriculture Act
This bill reauthorizes the Agriculture Advanced Research and Development Authority (AGARDA) through FY2032 and expands the program's environmental sustainability goals. This Department of Agriculture (USDA) program supports innovative research and development of technology, research tools, and products to address long-term and high-risk challenges related to food and agriculture.
The bill expands the program's goals to include
• water conservation;
• responding to greenhouse gas emissions; and
• resilience to drought, infectious diseases, and plant and animal pathogens and pests.
Show the full summary (3 more paragraphs)Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Referred to the Subcommittee on Conservation, Research, and Biotechnology.
Referred to the House Committee on Agriculture.
Introduced in House
Introduced in House
Actions from Congress.gov, newest first.
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 24, 2026.
1 citation.
VERTEX PHARMACEUTICALS INCORPORATED · lobbying firm or registrant: STANTON PARK GROUP
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 20, 2026 · issue area: Health Issues
$50,000
Paid to lobbying firm
…icals; Awareness of Cystic Fibrosis and Sickle Cell Disease; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; HR 7142 and S. 3832
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing